Diflunisal Drug Asset Due Diligence Report 2026

This Diflunisal Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

129

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Diflunisal can convert its Small molecule drug profile and COXs biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Diflunisal (query alias: diflunisal)
Modality / target	Small molecule drug; COXs; COX inhibitors
Highest global status	Approved
Originator	Merck & Co., Inc.
Active developers	Purpose Pharma International AB

The MCP disease footprint includes Amyloidosis, Hereditary, Transthyretin-Related. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
EUCTR2019-002873-80-ES	Phase 2/3	Ongoing	20	The primary analysis of the study will be the change in extracellular volume (CVD) measured by magnetic resonance using a T1 mapping technique before and after contrast at baseline and at 12 months of treatment.
NCT04113668	Phase 1	Completed	48	Maximum observed plasma concentration (Cmax) of BMS-986165 with and without UGT1A9 inhibitor
CTR20242116	Not Applicable	已完成	52	Not disclosed

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

The Effect of Diflunisal on Familial Amyloidosis

Phase 2/3; n=130; evaluation: not stated. Reported fields: Change from baseline to 2 years(Mean) = 26.3 units on a scale (95% Confidence Interval, 20.2 - 32.4); -; Change from baseline to 2 years(Mean) = 8.2 units on a scale (95% Confidence Interval, 2.9 - 13.6)

Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial

Phase 2/3; n=130; evaluation: Positive. Reported fields: Polyneuropathy progression = 25.0 points (95%CI, 18.4 - 31.6); Polyneuropathy progression = 8.7 points (95%CI, 3.3 - 14.1)

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Diflunisal addresses Amyloidosis, Hereditary, Transthyretin-Related. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 129 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: COXs records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2026-06-30	Azurity Pharmaceuticals Expands Portfolio with CONTRAVE® and Related Assets	Approved	Financial terms not disclosed
2026-05-19	清普生物科技与康联达医疗就 QP001 达成独家许可及供应协议	Approved	Financial terms not disclosed
2026-04-23	Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M	Discontinued	US$100.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Cancer cachexia treatment composition comprising diflunisal or a pharmaceutically acceptable salt thereof”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO